Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LONG-001
- Development stage
- Preclinical
- Lead developer
- Longaevus Technologies
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies
01
Overview
LONG-001 is a preclinical gene therapy candidate developed by Longaevus Technologies for the treatment of age-related inflammatory diseases, including psoriasis and rheumatoid arthritis. The therapy utilizes a lentiviral vector to deliver short hairpin RNA (shRNA) designed to inhibit a specific gene target identified through a screen of over 700 genes. This target plays a critical role in the inflammatory cascade triggered by the accumulation of DNA damage associated with cellular aging. By knocking down the activity of this gene, LONG-001 aims to suppress chronic inflammation and exert a rejuvenating effect on aged human cells, particularly primary skin fibroblasts.
Beyond the preview
Go deeper on LONG-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LONG-001.